Not Yet Recruiting PHASE2 INTERVENTIONAL 2-arm
NCT07137910
A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)
An Open-label, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B Previously Treated With Nucleos (t) Ide Analogues (NA)
Sponsor: Ausper Biopharma Co., Ltd.
Conditions
Chronic Hepatitis B
Interventions
AHB-137
Updated 1 time since 2025 Last updated: Aug 15, 2025 Started: Aug 27, 2025 Primary completion: Jan 1, 2026 Completion: Jun 1, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE2 clinical study on Chronic Hepatitis B, this trial is actively recruiting participants. The trial is conducted by Ausper Biopharma Co., Ltd. and has accumulated 1 data snapshot since 2025. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Ausper Biopharma Co., Ltd.
Data source: Ausper Biopharma Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .